First and second generation anti-EGFR tyrosine kinase inhibitors (TKIs) (e.g., erlotinib, gefitinib, afatinib) are first-line therapies for patients with EGFR mutation positive NSCLC, while conventional chemotherapy is recommended for patients who are EGFR wild type [7]. Here, EGFR is linked to non-small cell lung carcinoma.